Smartest Doc
Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients
The Prostate, 05/16/2012
Clinical Article
Goode RR et al. – PCA3 was found to be a better predictor of prostate cancer than PSA in the total population as well as the initial biopsy population, but was not superior to PSA in the repeat biopsy population.
Methods- PCA3 and PSA levels were obtained from 456 men with no known personal history of prostate cancer prior to prostate biopsy.
- Two hundred eighty-nine men underwent an initial prostate biopsy and 167 underwent a repeat prostate biopsy.
- PCA3 and PSA levels were compared to the prostate biopsy results.
- PCA3 score was shown to be independent of prostate volume (P = 0.162) and PSA level (P = 0.959).
- PCA3 scores were significantly higher in patients with cancer on prostate biopsy compared to patients with negative biopsy results (P < 0.0001).
- In logistic regression, PCA3 showed a significantly higher AUC than PSA (0.726 vs. 0.512, P = 0.0001).
- This difference persisted when examining the initial biopsy subgroup, with PCA3 out-performing PSA (AUC 0.772 vs. AUC = 0.552, P < 0.0001), but not in the repeat biopsy subgroup (AUC = 0.605 vs. AUC = 0.500, P = 0.2488).
